跳至主要内容

Early Toxicity Screening: These Strategies will help you.

 Early Toxicity Screening

Table of Contents

  1. 1. Computer-aided prediction model
  2. 2. In vitro high-throughput screening models
  3. 3. In vivo screening models

In innovative drug development, conducting toxicology studies to determine the type, dose, and mechanism of toxic response to a drug is essential to deciding on a drug’s safety and efficacy, developing safe drug use strategies, and avoiding unnecessary drug toxicities.

Generally, drug toxicology research includes the following :

  1. Toxicity testing: drug toxicity tests are conducted in experimental animals or cells to assess the harmful effects of drugs on organisms.
  2. Mechanism of toxicity studies: To understand the causes of toxic reactions by studying the mechanism of action of drugs.
  3. Toxicity assessment: To assess drug safety and potential risks and develop reasonable drug use strategies.
  4. Toxicological monitoring: to monitor the population using the drug and understand the long-term toxicity and adverse effects.

In the early stage of R&D, the early combination of toxicological screening and evaluation can help improve the success rate of innovative drug development and accelerate the R&D process.

Three main early drug toxicity evaluation methods exist: virtual, in vitro, and in vivo. Let’s take stock of several common drug early toxicity screening strategies today.

1. Computer-aided prediction model

Computer-aided prediction models are qualitative or quantitative predictions based on molecular structure information of compounds and help in the preferential selection of lead compounds.

In cardiac myocytes, the hERG potassium channel affects the repolarization process of the cardiac action potential. In recent years, several drugs have been withdrawn from the market because blocking this channel causes prolongation of the QT interval.

Using computer-aided drug design (CADD) to predict the potential hERG toxicity of drugs and guide drug design and modification is convenient, fast, and inexpensive. Researchers have developed many models and tools to predict hERG toxicity.

Quantitative structure-activity relationship (QSAR) modeling is an efficient and straightforward computer simulation method for predicting the potentially toxic effects of other compounds with known structures on the body by modeling a group of compounds’ structure and harmful effect data.

2. In vitro high-throughput screening models

1. Genetic toxicity

Genotoxicity evaluation is a key part of drug safety evaluation research, not only is it one of the important indicators for early toxicity screening of lead compounds, but also an important evaluation method and technique in standardized preclinical drug safety evaluation research, which is an important basis for judging whether a new drug can enter clinical trials.

For example, the bacterial revertant mutation test (Ames)  can sensitively detect mutations caused by DNA damage and occupies an important position in the early stage of new drug development.

2. Cardiotoxicity

The prolongation of OT intervals, which causes tachycardia of the tip-twist type and lethal arrhythmias, is an important issue that must be considered during the development of innovative drugs. 

IKr plays a critical role in the overall action potential time course. National drug regulatory authorities require new chemical entities to undergo a comprehensive hERG activity and QT interval evaluation following International Conference on Harmonization (ICH) guidelines. 

Establishing a cardiotoxicity evaluation system for hERG potassium channels is essential to save time and cost in developing new drugs. The diaphragm clamp technique is the most commonly used method to detect the hERG cardiotoxicity of drugs.

3. Nephrotoxicity

The kidney is the most common target organ of drug toxicity, and the traditional kidney function test method mainly relies on biochemical blood indexes. The abnormal increase of these indexes often indicates that the kidney function has been moderately damaged or above.

Predicting the nephrotoxicity of drugs is an essential part of drug safety evaluation. Establishing an in vitro nephrotoxicity optimization screening model is necessary to reduce the cost of drug development and accelerate the research and development process.

4. Hepatotoxicity

Hepatic transporter proteins play an important role in bile formation and drug disposition. Drug-transporter protein interactions are associated with hepatotoxicity; therefore, hepatotoxicity plays a vital role in drug metabolism and clearance and needs to be evaluated in preclinical studies of new drugs.

The in vitro culture model of hepatocytes is widely used for in vitro hepatotoxicity screening. In addition, in vitro models constructed using organ-on-a-chip technology offer some significant advantages for assessing the drug-induced liver injury.

3. In vivo screening models

Pharmacologists and toxicologists favor the model organism zebrafish due to advantages such as a wide range of toxicological endpoints, a small number of samples used, a short test cycle, and the similarity of tissue structure to mammals. 

Zebrafish are used to identify the potential toxicity and safety of various drugs and chemicals to various organs, and as an organic holistic life form, they can serve as an effective link between in vitro cell or tissue culture models and in vivo mammalian models.

Zebrafish models have been shown to have potential applications in predicting general toxicity (acute toxicity, developmental toxicity) and target organ toxicity (liver, heart, ototoxicity, etc.) as well.

Toxicity is a significant cause of failure in late-stage drug development. Early toxicity evaluation of compounds can significantly improve the success rate of drug development and reduce the occurrence of toxic side effects. Bringing safety evaluation to the early stage of drug development can help shorten the drug development cycle and reduce development costs.

Medicilon boasts professional teams and practical experience in drug safety evaluation and can promise high-quality data and fast turnaround time to support various drug safety evaluations. Our toxicology research uses different animals, from dose design and experimental research to histological and pathological study (including clinical detection). The analysis can be carried out according to non-GLP or GLP standards.

Recommend Reading

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文